Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 3.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,332,792 shares of the company’s stock after selling 44,132 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Olema Pharmaceuticals were worth $7,769,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of OLMA. Walleye Capital LLC purchased a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at approximately $391,000. XTX Topco Ltd increased its holdings in Olema Pharmaceuticals by 89.6% in the fourth quarter. XTX Topco Ltd now owns 48,032 shares of the company’s stock valued at $280,000 after buying an additional 22,700 shares in the last quarter. Barclays PLC raised its position in shares of Olema Pharmaceuticals by 21.0% in the fourth quarter. Barclays PLC now owns 114,879 shares of the company’s stock worth $669,000 after acquiring an additional 19,964 shares during the period. Renaissance Technologies LLC raised its position in shares of Olema Pharmaceuticals by 435.0% in the fourth quarter. Renaissance Technologies LLC now owns 157,300 shares of the company’s stock worth $917,000 after acquiring an additional 127,900 shares during the period. Finally, Aristides Capital LLC purchased a new stake in shares of Olema Pharmaceuticals during the 4th quarter worth about $189,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Olema Pharmaceuticals Trading Down 1.5%

NASDAQ:OLMA opened at $4.60 on Monday. The stock has a 50 day moving average of $4.27 and a two-hundred day moving average of $6.29. Olema Pharmaceuticals, Inc. has a 12 month low of $2.86 and a 12 month high of $16.62. The firm has a market cap of $314.46 million, a P/E ratio of -2.10 and a beta of 2.03.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.12. On average, research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on OLMA shares. JPMorgan Chase & Co. cut their price objective on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, March 28th. Oppenheimer restated an “outperform” rating and set a $25.00 price objective (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research report on Monday, April 28th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.